XTL Biopharmaceuticals Acquires NeuroNOS to Enhance Autism Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy XTLB?
Source: Globenewswire
XTL Biopharmaceuticals Ltd. saw a pre-market price increase of 8.40% as it crossed above its 20-day SMA.
The company announced its acquisition of 85% of NeuroNOS for $32.5 million, aiming to develop disease-modifying therapies for autism. This strategic move brings together a renowned scientific team, including Nobel Laureates, and positions XTL to address a significant market gap, especially given the lack of FDA-approved therapies for autism. The acquisition also includes FDA orphan drug designations for NeuroNOS's products, ensuring market exclusivity and expedited review, which enhances their competitive edge.
This acquisition not only strengthens XTL's portfolio but also opens up substantial market opportunities in the autism treatment space, where demand is urgent and unmet.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XTLB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XTLB
About XTLB
X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk with $47,000 Equity Deficit
- Delisting Risk Notification: XTL Biopharmaceuticals received a notice from Nasdaq on January 20, 2026, indicating non-compliance with continued listing requirements due to a stockholders' equity deficit, highlighting the company's precarious financial situation.
- Equity Deficit: The company's Form 6-K filed on December 30, 2025, revealed a $47,000 stockholders' equity deficit, indicating poor financial health that could undermine investor confidence.
- Compliance Evaluation: The company stated it is evaluating options to regain compliance and intends to act within Nasdaq's required timeframe, demonstrating its commitment to addressing the issue.
- Potential Market Impact: Failure to restore compliance in a timely manner could lead to delisting, adversely affecting the company's ability to raise capital and damaging its market reputation, thereby increasing operational uncertainties going forward.
See More
Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
- New Drug Approval: Sanofi's Teizeild receives EU approval as the first disease-modifying therapy for Stage 2 Type 1 Diabetes, demonstrating a median delay of 48.4 months to Stage 3 T1D, significantly enhancing patient quality of life and strengthening the company's competitive position in diabetes treatment.
- FDA Approval: Fortress Biotech's ZYCUBO gains FDA approval as the first treatment for Menkes Disease, showing nearly an 80% reduction in mortality risk when used early, laying a solid foundation for future market expansion and revenue growth.
- Acquisition Deal: Boston Scientific's $14.5 billion acquisition of Penumbra reflects its strategic expansion in interventional therapies, expected to enhance its leadership in vascular treatments and drive future revenue growth.
- Clinical Trial Progress: Creative Medical's CELZ-201 shows significant improvement in 79% of patients in the ADAPT trial for chronic lower back pain, indicating the therapy's clinical potential and likely attracting further investment and partnership opportunities.
See More
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
- Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
- Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
- Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
- Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.
See More
XTL Biopharmaceuticals Acquires 85% of NeuroNOS for $1M and Up to $32.5M in Milestones
- Acquisition Details: XTL will acquire 85% of NeuroNOS for 19.9% of its issued share capital, $1 million in cash, and contingent milestone payments up to $32.5 million, marking a strategic move into autism and neuro-oncology therapeutics.
- Positive Market Reaction: Following XTL's announcement to acquire NeuroNOS, shares of Beyond Air (XAIR) surged 149%, while XTLB shares rose 51% at the time of writing, indicating strong market approval of the deal.
- Autism Treatment Platform: NeuroNOS's drug development platform focuses on addressing the molecular mechanisms of autism, contrasting with existing treatments based on behavioral symptoms, which is expected to provide XTL with new therapeutic avenues in autism and neuro-oncology.
- Enhanced Policy Support: The U.S. government has allocated $50 million in NIH funding for autism research, reflecting a heightened focus on new drug development, which may provide XTL with policy backing and financial support for future growth.
See More
Beyond Air (XAIR) Sells 85% of NeuroNOS for Up to $32.5 Million
- Transaction Details: Beyond Air has entered into an agreement with XTL Biopharmaceuticals to sell 85% of its subsidiary NeuroNOS, which includes 19.9% of XTL's shares, $1 million in cash, and up to $32.5 million in milestone payments, indicating a strategic move in the biopharmaceutical sector.
- Market Potential: This deal positions XTL to become a key player in the rapidly growing autism therapeutics market, addressing critical global healthcare needs, particularly for underserved patient populations, thus holding significant social value and commercial prospects.
- R&D Support: NeuroNOS focuses on autism and neuro-oncology treatments and holds FDA Orphan Drug Designations, providing market exclusivity and accelerated approval pathways, which are expected to yield up to $5.5 million in clinical development payments for Beyond Air, facilitating its R&D progress.
- Shareholder Value Enhancement: Beyond Air's CEO Steve Lisi stated that this transaction validates the scientific foundation of NeuroNOS and creates significant value for shareholders, as it is expected to drive the advancement of NeuroNOS's pipeline with dedicated resources and funding.
See More
XTL Biopharmaceuticals Acquires 85% of NeuroNOS to Target Autism Treatment Market
- Enhanced Scientific Leadership: XTL's acquisition of 85% of NeuroNOS integrates a team led by Nobel Laureates and global autism researcher Haitham Amal, aiming to develop therapies targeting the core biological mechanisms of autism, addressing the critical lack of FDA-approved disease-modifying treatments.
- Significant Market Opportunity: With 1 in 31 children in the U.S. affected by autism and no FDA-approved disease-modifying therapies available, XTL's acquisition positions it as a key player in the rapidly expanding autism treatment market.
- FDA Orphan Drug Designations: NeuroNOS has secured FDA orphan drug designations for Phelan-McDermid Syndrome and Glioblastoma, providing seven years of market exclusivity and tax credits for clinical trial costs, enhancing XTL's competitive edge in autism therapeutics.
- Clear Transaction Terms: XTL acquires NeuroNOS for 19.9% equity, $1 million in cash, and up to $32.5 million in milestone payments, ensuring funding support for clinical development and commercialization to expedite the launch of autism treatment products.
See More
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk with $47,000 Equity Deficit
- Delisting Risk Notification: XTL Biopharmaceuticals received a notice from Nasdaq on January 20, 2026, indicating non-compliance with continued listing requirements due to a stockholders' equity deficit, highlighting the company's precarious financial situation.
- Equity Deficit: The company's Form 6-K filed on December 30, 2025, revealed a $47,000 stockholders' equity deficit, indicating poor financial health that could undermine investor confidence.
- Compliance Evaluation: The company stated it is evaluating options to regain compliance and intends to act within Nasdaq's required timeframe, demonstrating its commitment to addressing the issue.
- Potential Market Impact: Failure to restore compliance in a timely manner could lead to delisting, adversely affecting the company's ability to raise capital and damaging its market reputation, thereby increasing operational uncertainties going forward.
See More
Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
- New Drug Approval: Sanofi's Teizeild receives EU approval as the first disease-modifying therapy for Stage 2 Type 1 Diabetes, demonstrating a median delay of 48.4 months to Stage 3 T1D, significantly enhancing patient quality of life and strengthening the company's competitive position in diabetes treatment.
- FDA Approval: Fortress Biotech's ZYCUBO gains FDA approval as the first treatment for Menkes Disease, showing nearly an 80% reduction in mortality risk when used early, laying a solid foundation for future market expansion and revenue growth.
- Acquisition Deal: Boston Scientific's $14.5 billion acquisition of Penumbra reflects its strategic expansion in interventional therapies, expected to enhance its leadership in vascular treatments and drive future revenue growth.
- Clinical Trial Progress: Creative Medical's CELZ-201 shows significant improvement in 79% of patients in the ADAPT trial for chronic lower back pain, indicating the therapy's clinical potential and likely attracting further investment and partnership opportunities.
See More
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
- Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
- Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
- Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
- Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.
See More
XTL Biopharmaceuticals Acquires 85% of NeuroNOS for $1M and Up to $32.5M in Milestones
- Acquisition Details: XTL will acquire 85% of NeuroNOS for 19.9% of its issued share capital, $1 million in cash, and contingent milestone payments up to $32.5 million, marking a strategic move into autism and neuro-oncology therapeutics.
- Positive Market Reaction: Following XTL's announcement to acquire NeuroNOS, shares of Beyond Air (XAIR) surged 149%, while XTLB shares rose 51% at the time of writing, indicating strong market approval of the deal.
- Autism Treatment Platform: NeuroNOS's drug development platform focuses on addressing the molecular mechanisms of autism, contrasting with existing treatments based on behavioral symptoms, which is expected to provide XTL with new therapeutic avenues in autism and neuro-oncology.
- Enhanced Policy Support: The U.S. government has allocated $50 million in NIH funding for autism research, reflecting a heightened focus on new drug development, which may provide XTL with policy backing and financial support for future growth.
See More
Beyond Air (XAIR) Sells 85% of NeuroNOS for Up to $32.5 Million
- Transaction Details: Beyond Air has entered into an agreement with XTL Biopharmaceuticals to sell 85% of its subsidiary NeuroNOS, which includes 19.9% of XTL's shares, $1 million in cash, and up to $32.5 million in milestone payments, indicating a strategic move in the biopharmaceutical sector.
- Market Potential: This deal positions XTL to become a key player in the rapidly growing autism therapeutics market, addressing critical global healthcare needs, particularly for underserved patient populations, thus holding significant social value and commercial prospects.
- R&D Support: NeuroNOS focuses on autism and neuro-oncology treatments and holds FDA Orphan Drug Designations, providing market exclusivity and accelerated approval pathways, which are expected to yield up to $5.5 million in clinical development payments for Beyond Air, facilitating its R&D progress.
- Shareholder Value Enhancement: Beyond Air's CEO Steve Lisi stated that this transaction validates the scientific foundation of NeuroNOS and creates significant value for shareholders, as it is expected to drive the advancement of NeuroNOS's pipeline with dedicated resources and funding.
See More
XTL Biopharmaceuticals Acquires 85% of NeuroNOS to Target Autism Treatment Market
- Enhanced Scientific Leadership: XTL's acquisition of 85% of NeuroNOS integrates a team led by Nobel Laureates and global autism researcher Haitham Amal, aiming to develop therapies targeting the core biological mechanisms of autism, addressing the critical lack of FDA-approved disease-modifying treatments.
- Significant Market Opportunity: With 1 in 31 children in the U.S. affected by autism and no FDA-approved disease-modifying therapies available, XTL's acquisition positions it as a key player in the rapidly expanding autism treatment market.
- FDA Orphan Drug Designations: NeuroNOS has secured FDA orphan drug designations for Phelan-McDermid Syndrome and Glioblastoma, providing seven years of market exclusivity and tax credits for clinical trial costs, enhancing XTL's competitive edge in autism therapeutics.
- Clear Transaction Terms: XTL acquires NeuroNOS for 19.9% equity, $1 million in cash, and up to $32.5 million in milestone payments, ensuring funding support for clinical development and commercialization to expedite the launch of autism treatment products.
See More
